Depomed Announces Issuance of Formulation Patent Covering Gralise® (gabapentin)

Depomed, Inc. DEPO today announced the issuance of a new patent expanding the patent estate around the company's Gralise® (gabapentin), Depomed's once-daily gabapentin product approved for the management of postherpetic neuralgia. The patent, United States Patent No. 8,192,756, expires in October 2022 and will be listed in the FDA "Orange Book" along with the six patents currently listed for Gralise.